We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




In Vivo Molecular Imaging Agents Help in Early Disease Detection and Treatment

By Biotechdaily staff writers
Posted on 29 Mar 2007
A new line of imaging agents for in vivo molecular imaging applications allows non-invasive measurement of biologic processes within a living organism. More...
In contrast to conventional diagnostic imaging that highlights conditions caused by disease, molecular imaging identifies molecular abnormalities that are the basis of disease at a very early stage, which can accelerate the development of treatment alternatives that could help cure that disease.

Once attached to a molecule and injected into an organism, X-Sight imaging agents, developed by Eastman Kodak Molecular Imaging Systems group (Rochester, NY, USA), will travel to the target (such as a tumor) and highlight the region of interest. X-Sight imaging agents are non-toxic, making them safe for research studies in areas such as oncology, cardiology, diabetes, and inflammation. They are uniquely designed to provide significant advantages over currently available agents, enabling researchers to perform innovative research studies that could lead to a better understanding of the origin of these diseases.

X-Sight imaging agents deliver excellent brightness and enhanced stability, providing researchers a versatile platform for molecular imaging. These imaging agents are available in several distinct varieties and can be adapted to a wide range of applications.

"The launch of X-Sight Imaging Agents is a significant milestone toward offering our customers a complete solution of systems and agents to advance their research,” commented Shahram Hejazi, Ph.D., worldwide general manager of Kodak's Molecular Imaging Systems division. "This introduction strengthens our leadership in the molecular imaging arena as we move forward to bridge the gap between preclinical and clinical applications.”

X-Sight imaging agents are currently available for preclinical use in the United States and will be launched worldwide in March 2007. Kodak plans to introduce additional imaging agents throughout 2007.

Kodak's Molecular Imaging Systems group--part of Kodak's Health Group--develops and markets high performance digital imaging systems, imaging agents, film, and accessories for the life science research and drug discovery industries.


Related Links:
Kodak

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The POC diagnostic test aims to use fingerstick blood, serum, or plasma sample to detect typhoid fever (Photo courtesy of Adobe Stock)

POC Test Uses Fingerstick Blood, Serum, Or Plasma Sample to Detect Typhoid Fever

Typhoid fever is an acute febrile illness caused by Salmonella enterica serovar Typhi (S. Typhi) and affects an estimated 11–21 million people globally each year, resulting in approximately 128,000–161,000... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Industry experts gather at WHX Labs Dubai to discuss how leadership must adapt as AI and automation transform the laboratory (Photo courtesy of Shutterstock)

WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories

WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.